Evidence item

The reported 10.6-month median PFS is an interim duration estimate at 17.0 months’ median follow-up, not a lifetime or final estimate. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 25929

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:d3508dd7e3840d83f99041657a5d1da3b8c2d9b989bf3c4f568c168e91cc5639

With a median follow-up of 17.0 months, the median progression-free survival was 10.6 months (95% CI 7.8–17.4) and median overall survival was not reached.